Keryx Biopharmaceuticals to Present at the 31st Annual JP Morgan Healthcare …
Keryx Biopharmaceuticals to Present at the 31st Annual JP Morgan Healthcare …
Filed under: drug treatment programs in san francisco
The U.S.-based Phase 3 clinical program of Zerenex for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is being conducted pursuant to a Special Protocol Assessment (SPA) agreement with the FDA …
Read more on MarketWatch (press release)
Acorda Therapeutics Provides Corporate Update at 31st Annual JP Morgan …
Filed under: drug treatment programs in san francisco
President and CEO Ron Cohen, M.D. will provide a corporate overview, including the Company's recent acquisition of Diazepam Nasal Spray, at the 31st Annual J.P. Morgan Healthcare Conference today at 11:00 a.m. Pacific Time in San Francisco. … "AMPYRA …
Read more on MarketWatch (press release)
Isis Pharmaceuticals to Present at the 31st Annual JP Morgan Healthcare …
Filed under: drug treatment programs in san francisco
Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners. Isis' broad pipeline consists of 28 drugs to treat a wide variety of diseases with an emphasis on …
Read more on MarketWatch (press release)
Transcept obsessive compulsive disorder drug fails mid-stage study
Filed under: drug treatment programs in san francisco
Drug development. Transcept obsessive compulsive disorder drug fails mid-stage study … did not meet its primary endpoint, in particular for those suffering from treatment-resistant OCD," Transcept President and CEO Glenn Oclassen said in a press …
Read more on San Francisco Business Times (blog)